Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Eglin AFB Regional Hospital |
---|---|
Information provided by: | Eglin AFB Regional Hospital |
ClinicalTrials.gov Identifier: | NCT00445354 |
This study will randomize diabetics with hemoglobin A1c greater than 7.0 to receive either cinnamon plus usual care or usual care alone. Hemoglobin A1c will be measured at intake and after 90 days.
Condition | Intervention | Phase |
---|---|---|
Diabetes |
Drug: cinnamon |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Randomized Controlled Clinical Trial Comparing the Effect of 1g of Daily Cinnamon Plus Usual Care to Usual Cre on the Hemoglobin A1c of Uncontrolled Type 2 Diabetics |
Estimated Enrollment: | 140 |
Study Start Date: | March 2007 |
Estimated Study Completion Date: | August 2007 |
As the worldwide incidence of diabetes increases, the search for dietary adjuncts to treat this life-altering disease becomes far ranging. Cinnamon is purported to be a natural insulin sensitizer without any known adverse events. Both in vitro and in vivo animal studies have shown that cinnamon is an insulin sensitizer1. Several compounds within cinnamon have been identified as possible sources of this sensitization process.
To-date, three small randomized trials studying cinnamon in human diabetics have been published. Khan et al. reported that fasting serum glucose could be reduced by 18-29% after 40 days of supplementation with 1, 3, or 6 g of cinnamon (Cinnamomum cassia) in type 2 diabetics. 2 This study had several limitations that included failure to measure hemoglobin A1C, all patients were Pakistani, and no power analysis was documented. Vanschoonbeek, et al.3 report a small RCT of postmenopausal women with well-controlled type 2 diabetes which showed no change in HbA1C or fasting glucose. Once again no power analysis is reported. Mang et al. 4 conducted a RCT of type 2 diabetics treated with aqueous extract of cinnamon for 4 months. They report a 15% decrease in fasting glucose and no change in HbA1C over the duration of this trial. Subjects had HbA1C less than 7% and again no power analysis was included in this study.
This study will address whether cinnamon at the dose of 1g daily in addition to usual care lowers hemoglobin A1c compared to usual care. Power analysis indicates that 63 per group are needed and we will recruit 70 patients.
Ages Eligible for Study: | 18 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Paul Crawford, MD | 850-883-8879 | paul.crawford2@eglin.af.mil |
United States, Florida | |
Eglin AFB Regional Hospital | Recruiting |
Eglin AFB, Florida, United States, 32542 | |
Contact: James Whitworth, PhD 850-883-8288 james.whitworth@eglin.af.mil | |
Principal Investigator: Paul F Crawford, MD | |
Sub-Investigator: Karen L Weis, PhD |
Principal Investigator: | Paul F Crawford, MD | Eglin AFB Hospital |
Study ID Numbers: | FWH20060194H |
Study First Received: | March 7, 2007 |
Last Updated: | March 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00445354 |
Health Authority: | United States: Federal Government |
cinnamon diabetes hemoglobin a1c |
Diabetes Mellitus |